IL17A and leukemia: In this study, we found that IL-17A promoted but anti-IL-17A monoclonal antibodies (mAbs) treatment reduced leukemia cells’ homing, suggesting that anti-IL-17A mAbs treatment may render leukemia cells more sensitive to standard chemotherapeutic drugs.